Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lebrikizumab
Pharma
Lilly suffers another FDA snub, this time for lebrikizumab
After laying out a goal to launch four new drugs in 2023, Eli Lilly has run into yet another regulatory snag.
Fraiser Kansteiner
Oct 2, 2023 11:06am
Almirall turns to fine art to debunk atopic dermatitis myths
Sep 14, 2023 12:04pm
Eli Lilly is making a gung-ho push into immunology
May 19, 2022 10:14am